We propose a novel technical, regulatory, and cultural solution to support research on COVID- 19 and establish the open infrastructure required to respond to the next pandemic: ICEES+ COVID-19. The proposed work will build on the prior work that our team has been engaged with as part of the Biomedical Data Translator program (?Translator?), funded by the National Center for Advancing Translational Sciences (NCATS), to research and develop the Integrated Clinical and Environmental Exposures Service (ICEES). ICEES represents a unique, disease-agnostic framework and approach to support open sharing of and research on sensitive patient data that have been integrated at the patient and visit level with public exposures data. Importantly, ICEES has been validated in the context of our initial driving use case on asthma. We will extend this effort to instantiate an ICEES+ COVID-19 open infrastructure, focused on patients at UNC Health who have been tested (positive or negative) for COVID-19. The proposed work will leverage not only our prior Translator work, but also new work that our team has been engaged with as part of the NCATS Center for Data to Health (CD2H) National Covid Cohort Collaborative (N3C). Indeed, the North Carolina Translational and Clinical Sciences Institute (home to UNC?s CTSA) was selected by CD2H leadership to lead the technical implementation of significant portions of the N3C initiative. We will adopt the N3C COVID-19 consensus phenotype for the proposed work and extend the captured data fields to include relevant data fields that were intentionally excluded by the N3C collaborative in their effort to promote uniformity and participation, but are available via our local clinical data warehouse, such as temperature, oxygen saturation, isolation flags, and other potentially relevant clinical features (e.g., blood type). We also have partnered with investigators affiliated with the Environmental Polymorphisms Registry at the National Institute for Environmental Health Sciences and will be exposing data on their registry participants. Our overall aims are to develop and deploy ICEES+ COVID-19, apply ICEES+ COVID-19 to support research on COVID-19, and promote widespread use of ICEES+ COVID-19, largely through our engagement with the Translator program, CD2H N3C, and other large-scale collaboratives. A key aspect of the proposed work is that ICEES+COVID-19 will be open source, which will allow other institutions to rapidly adopt our approach and expose their data for open analysis of COVID-19 data by a much larger community. Collectively, the proposed work will catalyze efforts to respond to the COVID-19 pandemic and position society to be better prepared for the next one.

Public Health Relevance

The proposed ?ICEES+ COVID-19? represents a novel technical, regulatory, and cultural solution to openly share otherwise sensitive patient data that have been integrated with public environmental exposures data of relevance to the COVID-19 pandemic. As an open framework and approach, ICEES+ COVID-19 will democratize research on COVID-19, serve as an exemplar for adoption elsewhere, and support preparedness for the next pandemic.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR002489-03S4
Application #
10158906
Study Section
Program Officer
Chang, Soju
Project Start
2020-06-01
Project End
2022-02-28
Budget Start
2020-08-03
Budget End
2021-02-28
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Philpott, Hamish; Dellon, Evan (2018) Histologic improvement after 6 weeks of dietary elimination for eosinophilic esophagitis may be insufficient to determine efficacy. Asia Pac Allergy 8:e20
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Hibbard, Jonathan C; Friedstat, Jonathan S; Thomas, Sonia M et al. (2018) LIBERTI: A SMART study in plastic surgery. Clin Trials 15:286-293
Lee, Craig R; Sriramoju, Vindhya B; Cervantes, Alexandra et al. (2018) Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Circ Genom Precis Med 11:e002069
Peery, Anne F; Cools, Katherine S; Strassle, Paula D et al. (2018) Increasing Rates of Surgery for Patients With Nonmalignant Colorectal Polyps in the United States. Gastroenterology 154:1352-1360.e3
Mock, Meredith G; Hirsch, Katie R; Blue, Malia N M et al. (2018) Post-Exercise Ingestion of Low or High Molecular Weight Glucose Polymer Solution Does Not Improve Cycle Performance in Female Athletes. J Strength Cond Res :
Lewek, Michael D; Raiti, Cristina; Doty, Amanda (2018) The Presence of a Paretic Propulsion Reserve During Gait in Individuals Following Stroke. Neurorehabil Neural Repair 32:1011-1019
Buse, John B; Carlson, Anders L; Komatsu, Mitsuhisa et al. (2018) Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. Diabetes Obes Metab 20:2885-2893
James, Theodore W; Crockett, Seth D (2018) Management of acute pancreatitis in the first 72 hours. Curr Opin Gastroenterol 34:330-335
Antoniak, Silvio; Tatsumi, Kohei; Schmedes, Clare M et al. (2018) Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 122:80-87

Showing the most recent 10 out of 76 publications